What it is
Retatrutide plus Tirzepatide is a community- and vendor-named pairing, not a manufacturer-developed combination: Retatrutide activates GLP-1, GIP, and glucagon receptors, while Tirzepatide activates GLP-1 and GIP receptors, with no clinical study having evaluated the two together.
In this article
🧪 Load this blend into the DIY blend calculator →
What it is
Retatrutide (LY3437943) is a single molecule that activates three receptors — GLP-1, GIP and glucagon. Tirzepatide (LY3298176) is a single molecule that activates two of those three — GIP and GLP-1. Pairing them is a community and vendor practice, not a pharmaceutical programme: there is no manufacturer development name for this combination the way CagriSema is Novo Nordisk’s name for cagrilintide plus semaglutide.
You will see the pairing sold under opaque vendor codes — AMP-2P is one such label, and parallel two-peptide codes exist at other sellers. Those names are catalogue SKUs, not standardized formulations: the vendors using them generally do not publish the composition, so two products bearing similar codes need not contain the same thing.
Why these are combined
The stated rationale is receptor coverage. In practice the coverage is mostly redundant: both compounds already act on GLP-1 and GIP, so the only receptor arm one adds over the other is retatrutide’s glucagon agonism — which retatrutide supplies on its own.
This is the substantive difference from an amylin-plus-incretin pairing such as CagriSema, where the two compounds genuinely act on separate pathways. Here the mechanistic argument for combining is weak on its face, and it has not been tested.
Key point: Retatrutide and Tirzepatide share two of their three receptor targets. Combining them stacks overlapping mechanisms rather than adding a distinct one, and no published trial has studied the combination.
What is not known
Retatrutide has published phase 2 obesity data as a single compound, and tirzepatide has an extensive published trial record as a single compound. Neither body of evidence describes the two used together.
There is no published trial, no pharmacokinetic characterization of the pair, no co-formulation stability data, and no established ratio. Anything asserting otherwise — including a vendor listing that pairs a code name with a specific milligram split — is describing a product decision, not a research finding.
The components
- Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, studied on its own for effects on body weight and metabolic markers.
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, studied on its own for glycaemic and body-weight outcomes.
Reconstitution and blending
These research compounds arrive as a dry powder. At the bench the powder is reconstituted (dissolved into a liquid solution) using bacteriostatic water, a specially purified water with a small preservative added to slow bacterial growth in the vial.
Because this is a combination rather than a single studied formulation, there is no published compatibility or stability work for the two peptides sharing one vessel. Compounds that are individually stable can degrade faster together, and any multi-compound mixture shortens a conservative beyond-use window. Where compatibility is unknown, the conservative bench practice is to reconstitute separately.
Our reconstitution and DIY blend calculators handle the per-cartridge volumes and beyond-use timing once you have decided what shares a cartridge.
Status in sport
WADA (the World Anti-Doping Agency) maintains the list of substances banned in competitive sport. Incretin compounds in this family are not currently on the WADA Prohibited List.
As of the 2026 cycle, GLP-1 compounds appear on the WADA Monitoring Program — tracked and watched, but not banned. This status can change in future list cycles, so verify it independently against the current year’s list.
Related reading
- Retatrutide
- Tirzepatide
- CagriSema — a combination that has been formally studied
- Full peptide reference library and stacking guide
- Reconstitution and blend calculators
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
Has Retatrutide plus Tirzepatide been studied in a clinical trial?
No. Both compounds have published trial records individually, but no clinical study has evaluated them in combination. Any claim about what the pairing does is extrapolation.
What is AMP-2P?
AMP-2P is a vendor product name applied to a two-peptide research blend in the incretin family. Sellers using it and comparable codes generally do not publish the composition, so the name identifies a catalogue item rather than a defined formulation. Treat the code as a search term, not a specification, and rely on an assay for identity.
Do Retatrutide and Tirzepatide target different receptors?
They overlap. Retatrutide is a triple GLP-1/GIP/glucagon agonist and tirzepatide is a dual GIP/GLP-1 agonist, so both act on GLP-1 and GIP. The only receptor arm not shared is glucagon, which retatrutide already provides alone.
Are these compounds banned under WADA rules for 2026?
GLP-1 compounds appear on the 2026 WADA Monitoring Program — tracked but not currently prohibited. WADA classification can change in future annual cycles, so verify against the current list.
What the research community gets wrong about Retatrutide + Tirzepatide
- The receptor coverage largely duplicates. Both compounds hit GLP-1 and GIP. Describing the pair as covering "five receptor targets" double-counts the two they share.
- It is two peptides, not one. At the bench you are handling two separate research compounds. Label and track each one rather than treating the vial as a single ingredient.
- A vendor code name is not a specification. These pairings circulate under opaque product names that differ from seller to seller, and most sellers do not publish what is actually in them. A code name tells you nothing about identity, ratio, or purity — only an assay does.
- Single-compound trial data does not transfer to a combination. Published results describe one compound studied on its own, under a protocol. They say nothing about what two compounds do together, and nothing about a solution reconstituted at a bench.
- A reconstituted vial does not stay good forever. Peptides in solution break down over time, and rough handling (shaking hard enough to foam) can damage them. Note your reconstitution date and store the vial as your protocol calls for.
From our bench: If you have reconstituted a vial of this pairing, tell us what you actually observed. How long did the powder take to fully dissolve in bacteriostatic water, was the final solution clear or cloudy, and did any particles or haze appear after it sat cold? Share your own logged observations, not numbers copied from a label, so other researchers can compare notes.
Sources
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med, 2023
- PubChem Compound Summary: Tirzepatide
- Triple Agonism Based Therapies for Obesity — review, PMC12304053
- Bacteriostatic Water for Injection, USP — FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 — Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) — Handling and Storage Guidelines for Peptides and Proteins
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
